• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Valeritas inks distro deal in Australia, New Zealand for V-Go insulin delivery device

April 17, 2018 By Sarah Faulkner

Valeritas V-Go deviceValeritas (NSDQ:VLRX) said today that it inked an exclusive distribution deal with AMSL Diabetes and NZMS Diabetes for the commercialization of its V-Go wearable insulin delivery device in Australia and New Zealand.

According to the terms of the agreement, AMSL Diabetes and NZMS Diabetes retain the right to promote, market and sell the V-Go device to clinics and patients, while Valeritas remains responsible for regulatory and manufacturing activities. Financial terms of the deal were not disclosed.

“We are excited to offer the V-Go wearable insulin delivery device to patients with Type II diabetes in Australia and New Zealand, and thrilled to be partnered with AMSL and NZMS Diabetes,” president & CEO John Timberlake said in prepared remarks. “Our decision to partner with AMSL and NZMS Diabetes was driven by our goal of choosing the best distributor in Australia and New Zealand.”

“Adding V-Go to our portfolio is a significant step towards addressing the needs of Australian and New Zealand patients with Type II diabetes who want simple and effective insulin management that doesn’t interfere with their way of life,” Richard Plowright, managing director of AMSL and NZMS, added.

VLRX shares were up 19.4% in premarket activity today, trading at $1.48 apiece.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Diabetes, Distribution, Drug-Device Combinations, Featured, Wall Street Beat Tagged With: Valeritas Inc.

IN CASE YOU MISSED IT

  • Nuvo, Sheba Medical Center develop AI-powered gestational diabetes management platform
  • Verily’s Onduo, Sword Health collaborate on virtual diabetes care
  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS